An Intact C-terminus is Required for the Antimicrobial Effects of CCL28 in Host Defense from Oropharyngeal Candidiasis

Anna R. Huppler,Jie He,Brian F. Volkman,Mitchell H. Grayson

DOI: https://doi.org/10.4049/jimmunol.196.supp.205.7

2016-01-01

Abstract:Abstract Oropharyngeal candidiasis (OPC) is an opportunistic infection caused by the commensal fungus Candida albicans. There is an urgent need for new therapeutic candidates to manage mucosal infection and prevent progression to high mortality disseminated candidiasis. The T helper 17 (Th17)-associated cytokines IL-23 and IL-17 are crucial for immunity to OPC. However, our recent work indicates the current model of IL-17-mediated defense is insufficient to completely explain susceptibility to OPC. CCL28 is a CC chemokine with antimicrobial peptide (AMP) activity that has a potential role in oral host defense. CCL28 is most abundant in the salivary gland and has in vitro antimicrobial activity against multiple pathogens including C. albicans. Little is known about the in vivo function or regulation of CCL28 in defense from infection. In the current study, we explore the motifs of CCL28 contributing to AMP activity and the relationship with OPC. We demonstrate that C. albicans killing by CCL28 at physiologic concentrations can be eliminated by truncation of the C-terminus. The N-terminus of CCL28, which is required for receptor binding, is dispensable for anti-fungal activity. In an in vivo model of OPC in mice, application of recombinant CCL28 reduces oral fungal burdens in immunodeficient mice. Ccl28 gene expression in salivary gland is suppressed at baseline in mice susceptible to OPC. Our results indicate that the CCL28 flexible C-terminal domain is an important functional motif for anti-Candida AMP activity, CCL28 treatment reduces mucosal fungal infection in vivo, and CCL28 may be a component of host defense from infection. CCL28 is a promising candidate for mucosal immunity and future development for treatment of Candida infections.